ViiV Healthcare @ EAS 2017
ViiV Healthcare held a webinar to discuss data for dolutegravir in the real-world setting, focusing on switching and tolerability in clinical practice. Additionally, an update was given on results from the Positive Perspectives Survey – an international patient survey of over 1,000 patients exploring their opinions on healthcare, stigma and treatment satisfaction.
Chapter 1: EU patient experience and views on antiretroviral treatment: Findings from the Positive Perspectives Study
Presented by Andrew Murungi, Medical Affairs Operations Director, ViiV Healthcare.
Chapter 2: Meta-analysis of safety for DTG versus other ARVs in randomised trials: Analysis of cardiovascular, CNS and IRIS endpoints
Presented by Dr. Annemiek de Ruiter, Senior Global Medical Director, ViiV Healthcare
Chapter 3: New data from EACS 2017: Latest dolutegravir clinical data
Presented by Prof. Jan Van Lunzen, Senior Global Medical Affairs Director, ViiV Healthcare
TRIUMEQ ▼ is indicated for the treatment of HIV-infected adults and adolescents above 12 years of age weighing at least 40kg.
Before initiating treatment with abacavir-containing products, HLA-B*5701 status must always be documented. Abacavir should not be used in patients known to carry the HLA-B*5701 allele due to the risk of hypersensitivity reaction.
TIVICAY ▼ is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-infected adults, adolescents and children aged 6 years and over, weighing at least 15kg.